Data from patients with hereditary angioedema (HAE) on their attack journeys and a patient preference study have been presented at the 2023 US HAEA National Summit in Orlando, Florida, KalVista Pharmaceuticals announced.
“The data presented at HAEA adds to the growing evidence that there remains an important unmet need for both people using only on-demand therapies as well as those on long-term prophylaxis,” said Andrew Crockett, chief executive officer of KalVista.
According to real-world evidence, patients recognize the onset of HAE attacks and report a need for rapid treatment solutions. However, many of them delay or deny themselves treatment due to several challenges associated with injections or infusions.
Continue Reading
When presented with a choice between oral and injectable on-demand treatments with similar efficacy and safety, most adult and adolescent HAE patients opt for orally administered medications.
Read more about HAE experimental therapies
KalVista is in the process of developing sebetralstat, an oral on-demand therapy for HAE attacks, as well as oral factor XIIa inhibitors. The enrollment target for the phase 3 KONFIDENT clinical trial investigating sebetralstat has been completed.
The clinical stage pharmaceutical company presented 3 posters at the HAEA Summit, titled “In their own words: patient descriptions of the earliest recognition of HAE attack onset” and “Recognizing the importance of early on-demand treatment in the HAE attack journey.” The last poster presentation was titled “Preferences of people with hereditary angioedema for on-demand treatment: a US-based qualitative study.”
Reference
KalVista Pharmaceuticals presents new HAE attack journey data at 2023 US HAEA National Summit. News release. KalVista Pharmaceuticals, Inc.; July 24, 2023.
